Opioid Peptide Met-Enkephalin Inhibits Cancer Cell Growth Through a Non-Classical Receptor
Opioid growth factor (OGF/met-enkephalin) inhibited human pancreatic, colon, and squamous cell cancer proliferation through a novel nuclear receptor (OGFr) activating p16 and p21 cell cycle inhibitors — a distinct anti-cancer opioid mechanism.
Quick Facts
What This Study Found
Met-enkephalin (OGF) inhibited cancer proliferation through OGFr nuclear translocation and activation of p16/p21 cell cycle inhibitors across pancreatic, colon, and squamous cell cancers — a non-classical opioid anti-cancer mechanism.
Key Numbers
How They Did This
In-vitro study using three human cancer cell lines. OGF binding, OGFr localization, p16/p21 induction, and cell cycle arrest measured. Classical opioid receptor involvement excluded with selective antagonists.
Why This Research Matters
A natural opioid peptide that suppresses cancer through tumor suppressor activation represents an entirely new anti-cancer mechanism. It could be boosted to enhance natural tumor control.
The Bigger Picture
The body has a built-in opioid-based tumor suppression system. Met-enkephalin naturally slows cancer growth through OGFr — boosting this system could be a novel cancer treatment strategy.
What This Study Doesn't Tell Us
In-vitro cancer cell lines. The OGFr pathway's in-vivo significance and therapeutic potential need validation.
Questions This Raises
- ?Could OGFr agonists be developed as cancer drugs?
- ?Is the OGF-OGFr pathway deficient in cancer patients?
- ?Would opioid drugs that block classical receptors inadvertently affect this anti-cancer pathway?
Trust & Context
- Key Stat:
- Built-in tumor suppression Met-enkephalin activates p16/p21 tumor suppressors through a nuclear receptor — the body has its own opioid-based cancer control system
- Evidence Grade:
- Preliminary in-vitro evidence across three cancer types with clear non-classical receptor identification and tumor suppressor activation.
- Study Age:
- Published in 2003. The OGF-OGFr pathway has been further characterized and is being explored for cancer therapy.
- Original Title:
- Opioids and the apoptotic pathway in human cancer cells.
- Published In:
- Neuropeptides, 37(2), 79-88 (2003)
- Authors:
- Zagon, Ian S(3), McLaughlin, Patricia J(3)
- Database ID:
- RPEP-00875
Evidence Hierarchy
Frequently Asked Questions
Can the body's opioids fight cancer?
Yes — met-enkephalin (an endogenous opioid) naturally slows cancer growth. It works through a special nuclear receptor (not the regular pain receptors) that activates tumor suppressors to halt cancer cell division.
Could this be used for cancer treatment?
The OGF-OGFr pathway is being explored for cancer therapy. Boosting this natural system — or preventing its loss in cancer — could complement existing treatments.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00875APA
Zagon, Ian S; McLaughlin, Patricia J. (2003). Opioids and the apoptotic pathway in human cancer cells.. Neuropeptides, 37(2), 79-88.
MLA
Zagon, Ian S, et al. "Opioids and the apoptotic pathway in human cancer cells.." Neuropeptides, 2003.
RethinkPeptides
RethinkPeptides Research Database. "Opioids and the apoptotic pathway in human cancer cells." RPEP-00875. Retrieved from https://rethinkpeptides.com/research/zagon-2003-opioids-and-the-apoptotic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.